Drug Pricing
Expert articles and analysis related to drug pricing.
AI Summary — Last 24 Hours
President Trump’s new pledge to impose tariffs on imported generic drugs—reported as up to 100% in 2028 and 200% in 2029—raises a direct cost and access risk for Medicare, Medicaid, ACOs, and value-based pharmacy strategies that rely on low-cost generics to manage total cost of care and medication adherence (AJMC). At the same time, Capitol Hill activity around drug-cost legislation and the Main Street Pharmacy Access Act/ECAPS is sharpening the tension between federal efforts to lower drug spending, strengthen oversight, and preserve community pharmacy access—key infrastructure for population health, chronic disease management, and medication therapy management in VBC contracts (Healthcare Innovation
Related Articles
Legislation Advances to Lower Drug Costs and Enhance Federal Oversight
Legislation Advances to Lower Drug Costs and Enhance Federal Oversight  HCI Innovation Group
Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029
The Data Problem Behind Prescription Drug Waste
Trump pledges new tariffs on generic drugs not made in the US
President Donald Trump on Tuesday evening said he will impose up to 200% tariffs on generic drugs sold in the US, if companies do not manufacture those medicines in America. Trump said that for the ...
STAT+: Pharmalittle: We’re reading about Trump’s plan for tariffs on generics, a Merck and Gilead HIV pill, and more
President Trump plans to impose tariffs on imported generic medicines, his latest threat aimed at bringing pharmaceutical manufacturing back to the U.S.
GLP-1s tied to 17% reduction in long-term sick leave: 4 study notes
GLP-1s tied to 17% reduction in long-term sick leave: 4 study notes  Becker's Hospital Review
Oncology Workflows Shift as Drug Delivery, Monitoring Change: Angie Maynard, PharmD, MS
Compounded GLP-1 drugs are not the same as approved ones
Compounded GLP-1 drugs are not the same as approved ones  KevinMD.com
$10B M&A Deal Pays Off With GSK’s First Lung Cancer Drug Approval
$10B M&A Deal Pays Off With GSK’s First Lung Cancer Drug Approval  MedCity News
STAT+: Pharma tries to tamp down broad China restrictions
AI-focused VC firm raises $800M, Merck's new cholesterol pill, and more biotech news from The Readout